Clinical Trial

A Study of Anti-CD38 Monoclonal Antibody (SG301) Subcutaneous Injection in Children With Nephrotic Syndrome With Frequent Relapses or Steroid Dependence

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is an open - label study to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of SG301 Subcutaneous injection in children with frequently relapsing or steroid - dependent nephrotic syndrome.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-07-17; most recent amendment 2026-02-26.
Status change: Not Yet Recruiting → Recruiting 2025-08-28
Trial Details
NCT Number NCT07087314
Lead Sponsor Mao Jianhua
Conditions Nephrotic Syndrome in Children
Enrollment 30 participants
Start Date 2025-08-25
Primary Completion 2028-07-09 (estimated)
Study Completion 2029-07-09 (estimated)
Updated on ClinicalTrials.gov 2026-02-27